Tacalyx
Tacalyx creates medications that target carbohydrate antigens unique to cancer on the surface of metastatic malignant tumors for which there are no effective treatments.
About Tacalyx
Tacalyx, founded in 2019, develops innovative therapeutics targeting tumor-associated carbohydrate antigens (TACAs) expressed on the surface of metastatic malignant tumors for which no satisfactory treatments currently exist. The company’s name is derived from “TACA” (Tumor-Associated Carbohydrate Antigen) and “Glycocalyx,” the glycan-rich layer that surrounds cells. Cancer cells differ from healthy cells by displaying aberrant carbohydrate structures that promote metastasis, angiogenesis, and immune system suppression. These abnormal glycosylation patterns make TACAs highly cancer-specific and attractive therapeutic targets. By focusing on these unique surface markers, Tacalyx aims to develop novel cancer treatments that disrupt tumor progression and improve outcomes for patients with aggressive and therapy-resistant cancers.
Recently Added Startups
Tacalyx
Tacalyx creates medications that target carbohydrate antigens unique to cancer on the surface of metastatic malignant tumors for which there are no effective treatments.
We Travel Hub
We Travel Hub is a tourism-focused affiliate platform connecting travelers, content creators, merchants, and advertisers, featuring Travelfinder to monetize travel content and streamline bookings.
FrontWave Imaging
FrontWave Imaging develops supercomputing software that aids in breast cancer diagnosis. Barcelona Supercomputing Center is the parent company of Frontwave Imaging S.L.
Related Post
Cambridge Innovation Capital Commits €115 Million To Spinouts From The University Of Cambridge
CatalYm funding news – Munich-based CatalYm Secures $150 Million in Series D Round Funding
Jälle Technologies Secures €2M In Pre-Seed Round
Berlin
Tacalyx
Tacalyx creates medications that target carbohydrate antigens unique to cancer on the surface of metastatic malignant tumors for which there are no effective treatments.
7Learnings
7Learnings is a leading Retail AI company helping retailers and brands boost performance through predictive pricing and marketing, delivering an average 10% profit uplift with data-driven, automated decision-making solutions.
Biotech
Tacalyx
Tacalyx creates medications that target carbohydrate antigens unique to cancer on the surface of metastatic malignant tumors for which there are no effective treatments.
Kintsugi Therapeutics
Kintsugi Therapeutics is a Barcelona based preclinical-stage biopharmaceutical company focused on the development of innovative therapies targeting ER stress for the treatment of NASH and other pathologies.
Germany
Tacalyx
Tacalyx creates medications that target carbohydrate antigens unique to cancer on the surface of metastatic malignant tumors for which there are no effective treatments.
Breakpoint Therapeutics
Breakpoint Therapeutics develops first-in-class oncology drugs targeting DNA damage response, disrupting repair and replication stress to treat resistant cancers.